Barclays Review of Medtronic (MDT); Continued Pressure in CRM/Spine Business; Core Demostrated Stability
Tweet Send to a Friend
Barclays maintains an 'Equalweight' on Medtronic, Inc. (NYSE: MDT) price target of $41.00.
Analyst, Adam Feinstein, said, "Growth in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Adam Feinstein, said, "Growth in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
